Is UNII-27T56C7KK0 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-27T56C7KK0? Is UNII-27T56C7KK0 safe for nursing mother and child? Does UNII-27T56C7KK0 extracts into breast milk? Does UNII-27T56C7KK0 has any long term or short term side effects on infants? Can UNII-27T56C7KK0 influence milk supply or can UNII-27T56C7KK0 decrease milk supply in lactating mothers?

UNII-27T56C7KK0 is a synthetic form of beta-glucocerebrosidase, which is a normal component of human milk. After therapeutic use of UNII-27T56C7KK0, breastmilk levels are lower than those of normal mothers.[1] Additionally, absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract.[2][3] A limited amount of data support the safety of breastfeeding with UNII-27T56C7KK0. An international panel of clinicians from 9 centers that treat Gaucher's disease reported that, breastfeeding complications were less frequent in mothers who were treated with UNII-27T56C7KK0 or alglucerase (the placenta-derived form of the enzyme) postpartum than in untreated mothers with Gaucher's disease. Consider limiting the duration of breastfeeding to about 6 months to avoid excessive bone loss in the nursing mother.[3][4]

One woman received alglucerase 30 international units/kg intravenously every 2 weeks during pregnancy and lactation. Her breastfed infant reportedly grew and developed normally.[7] A woman received UNII-27T56C7KK0 30 units/kg every 2 weeks during pregnancy and for 3 months while breastfeeding. The dose was then increased to 60 units/kg every 2 weeks because of disease progression, and she continued breastfeeding until the infant was 1 year old.[8] A woman receiving long-term therapy with UNII-27T56C7KK0 60 units/kg intravenously every 2 weeks became pregnant twice during therapy and breastfed both infants (extent not stated). Both infants developed normally during the observation periods of 13 and 33 months.[5] A woman with type 1 Gaucher's disease was exclusively breastfeeding her infant postpartum re-initiated intravenous UNII-27T56C7KK0 30 units/kg every 2 weeks beginning at 1 month postpartum. The infant was breastfed for about 9 months postpartum and was reportedly healthy when followed up to 3 years of age.[1] A woman with Gaucher's disease received UNII-27T56C7KK0 1800 units (30 units/kg) every 2 weeks during pregnancy and postpartum. Her infant was breastfed (extent not stated) and was followed by a pediatrician who determined that development was normal over 2 years.[9]